BAUSCH HEALTH COMPANIES WKN: A2JQ1X ISIN: CA0717341071 Kürzel: BHC Forum: Aktien Thema: Hauptdiskussion

Der Geduldsfaden wird dünner

Auf ein nächstes positives Ergebnis für q4 2020 🍻

Bei dem Kurs Niveau und guten Zahlen zu den aktuellen Umständen finde ich die Kursentwicklung mal wieder irrational.

Aber hier muss doch was anderes im Busch sein, gibt es weitere News?

Tja.. Der Markt ist nervös

Man zweifelt da irgendwie an seiner Realität, da kommen echt gute News und dann geht's runter.

Wahnsinn, vorbörslich waren wir schon bei 18,50 $. Die Shortys geben noch nicht auf.

Zu 14,65€ vielleicht ist der Markt enttäuscht weil nichts zum Spin off kam

Natoll ja habe bei der Begeisterung nochmal 11 Stück zusätzlich gekauft.

Und wieder runter 🤢

Endlich der Bilanzhinweis, dass sich zukünftig ein Gewinn ergibt weil der Schuldenstand soweit abgetragen wurde, dass nach Zinszahlungen noch Geld übrig bleibt!!!

https://seekingalpha.com/article/4384022-why-investors-should-buy-bausch-health-stock

Morgen gibts Zahlen und Infos zur Aufspaltung

https://ir.bauschhealth.com/events-and-presentations/2020

Danke dir

Bausch's rifaximin receives orphan drug status from FDA 2020-10-29 16:51 ET - News Release Mr. Joseph Papa reports BAUSCH HEALTH'S RIFAXIMIN RECEIVES FDA ORPHAN DESIGNATION FOR SICKLE CELL DISEASE The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Bausch Health Companies Inc.'s rifaximin for the treatment of sickle cell disease. The FDA's orphan drug designation program provides orphan status to medicines that are intended for the treatment of a rare disease or condition and incentives for companies to study and further develop medicines to bring forward novel treatments. Approximately 100,000 Americans have sickle cell disease, which is a group of inherited red blood cell disorders that affects hemoglobin, the protein that carries oxygen through the body. Patients with sickle cell disease have crescent or sickle-shaped red blood cells that can block blood flow through the body, which can lead to serious problems, including: stroke; eye problems; infections; and unpredicted episodes of vaso-occlusive crisis, which is described as sharp, intense, stabbing or throbbing pain that can strike nearly anywhere in the body and often requires intravenous pain medication. Sickle cell disease is a lifelong illness, and its only cure is a blood and bone marrow transplant. "Early data suggests that rifaximin may be beneficial in reducing vaso-occlusive crisis in patients with sickle cell disease, and we are currently finalizing trial protocols to further evaluate its potential in this patient population," said Joseph C. Papa, chairman and chief executive officer, Bausch Health. "We expect to start a phase 2 trial in the first half of 2021 evaluating a novel rifaximin formulation for a potential sickle cell disease treatment, and we are hopeful to be able to bring this investigational oral formulation forward to help sickle cell patients." About Bausch Health Companies Inc. Bausch Health is a global company with a mission to improve people's lives with the company's health care products. The company develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. It is delivering on its commitments as it builds an innovative company dedicated to advancing global health. We seek Safe Harbor. © 2020 Canjex Publishing Ltd. All rights reserved.